US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

28.24

+0.73002.65%

Volume:302.85K

Turnover:8.50M

Market Cap:4.98B

PE:-15.98

High:28.29

Open:27.91

Low:27.65

Close:27.51

Loading ...

Overview Company News Filings

Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

Zacks Small Cap Research

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OS/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":28.24,"timestamp":1750092042868,"preClose":27.51,"halted":0,"volume":302854,"delay":0,"floatShares":69821187,"shares":176260091,"eps":-1.766751,"marketStatus":"Trading","change":0.73,"latestTime":"06-16 12:40:54 EDT","open":27.91,"high":28.29,"low":27.65,"amount":8496005.358706001,"amplitude":0.023264,"askPrice":28.24,"askSize":450,"bidPrice":28.22,"bidSize":361,"shortable":3,"etf":0,"ttmEps":-1.766751,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750104000000},"marketStatusCode":2,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":27.51,"preHourTrading":{"tag":"盘前","latestPrice":28.35,"preClose":27.51,"latestTime":"09:28 EDT","volume":177,"amount":4909.08969,"timestamp":1750080480077},"postHourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.51,"latestTime":"19:35 EDT","volume":30730,"amount":843754.23,"timestamp":1749857751404},"volumeRatio":0.503873,"impliedVol":0.4336,"impliedVolPercentile":0.1991},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":69821187,"roa":"-35.83%","roe":"-108.78%","lyrEps":-1.232998,"volumeRatio":0.503873,"shares":176260091,"dividePrice":0,"high":28.29,"amplitude":0.023264,"preClose":27.51,"low":27.65,"week52Low":16.6942,"pbRate":"12.06","psRate":"9.66","week52High":35.39,"institutionHeld":0,"latestPrice":28.24,"committee":-0.109741,"eps":-1.766751,"divideRate":0,"volume":302854,"delay":0,"ttmEps":-1.766751,"open":27.91,"prevYearClose":28.52,"prevWeekClose":27.51,"prevMonthClose":28.06,"prevQuarterClose":21.34,"fiveDayClose":28.92,"twentyDayClose":28.27,"sixtyDayClose":22.17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518817229","title":"Press Release: Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518817229","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518817229?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:57","pubTimestamp":1741611420,"startTime":"0","endTime":"0","summary":"Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers. CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on serum biomarkers CEACAM1 and myeloperoxidase. NT219 headed into Phase 2 head and neck cancer study in combination with pembrolizumab  and in combination with cetuximab . \"We believe that our CAPTN-3 platform is well-positioned and differentiated in the T cell engagers  and multi-specific space, uniquely unleashes both innate and adaptive immune cells against the tumor, demonstrating synergistic effect of the T cell and NK cell activating arms. The unique NKG2A arm in the lead compound acts as a checkpoint inhibitor, enabling simultaneous NK and T cell activation, including effector subsets with high antitumor activity. We are excited about our CAPTN-3 collaboration with the Icahn School of Medicine at Mount Sinai. Our cash runway is expected","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4211","BK4195","BK4007","PPBT","PFS","ORR","BK4097"],"gpt_icon":0},{"id":"2517388304","title":"AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517388304","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517388304?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:54","pubTimestamp":1741352061,"startTime":"0","endTime":"0","summary":"On Friday, AstraZeneca Plc  released high-level results from the MATTERHORN Phase 3 trial evaluatingImfinzi as a perioperative treatment for patients with resectable Stage II-IVA gastric and gastroesophageal junction  cancers.The trial showed that perioperative treatment with Imfinziin combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival .Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal junction  cancers.A strong trend was observed for the secondary endpoint of overall survival  in favor of theImfinzi-based regimen. The trial will follow OS, which will be formally assessed at the final analysis.Gastric cancer is the fifth leading cau","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-based-regimen-shows-125421014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","SSI","AZN","LU2456880835.USD","LU0320765992.SGD","LU2417539215.USD","LU2236285917.USD","LU0109394709.USD","BK4097","BK4568","BK4585","LU1829250122.USD","LU2462157665.USD","BK4588","OS","LU0889565916.HKD"],"gpt_icon":0},{"id":"2517482850","title":"Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482850?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:30","pubTimestamp":1741350600,"startTime":"0","endTime":"0","summary":"Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall surv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038883/0/en/Plus-Therapeutics-Announces-Peer-Reviewed-Publication-in-Nature-Communications-Highlighting-Promising-Phase-1-Results-for-Rhenium-186Re-Obisbemeda-in-Glioblastoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4097","BK4202","NCI","OS","CNS","BK4139","LENZ"],"gpt_icon":0},{"id":"2517919484","title":"Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919484","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919484?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Promising Data in Anal Cancer with 33% Response Rate, Including a Durable 15+ Month Complete Response: In the ongoing GOBLET study, Oncolytics' pelareorep combination therapy achieved a 33% objective response rate , including a complete response lasting over 15 months, in twelve evaluable patients with second-line or later unresectable squamous cell carcinoma of the anal canal treated with pelareorep and atezolizumab . This encouraging signal in a very tough-to-treat disease further supports pelareorep's potential in solid tumors. The success criteria in Stage 1 of this Simon two-stage design were previously met; enrollment into Stage 2 of this cohort has begun and will add 18 additional","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-reports-highlights-financial-120000587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4211","ONCY","ORR","PFS","BK4195","BK4139","OS"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1829250122.USD","BK4500","LU2456880835.USD","HCC","BTC","BK4144","HSCT","BK4568","LU0320765992.SGD","LU0109394709.USD","LU2462157665.USD","BK4585","BK4213","BK4532","LU2236285917.USD","BK4588","LU2417539215.USD","CRT","BK4124","BK4582","VOD","BK4132","BK4006","BK4156","FLOT","BK4008","OS","BK4007","BK4097","LU0889565916.HKD","TEN","AZN","ALK"],"gpt_icon":0},{"id":"2517481546","title":"Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517481546","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517481546?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study. Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing. SAN DIEGO and CALGARY, AB, March 7, 2025 /PRNewswire/ -- Oncolytics Biotech  Inc.  , a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024. With its lead candidate, pelareorep, demonstrating strong efficacy signals in breast, pancreatic, and anal cancer, the company is strategically advancing toward registrational studies that could redefine treatment landscapes in multiple high-need indications. All dollar amounts are expressed in Canadian currency unless otherwise noted.GOBLET gastrointestinal cancer data continue to demonstrate pelareorep's potential across multiple indications. Oncolytics presented t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4139","ONCY","BK4232","OS","R","BK4022","ORR","BK4097","BK4211","BK4195"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0114720955.EUR","MYE","HSCT","LU1868836591.USD","VOD","OS","CRC","LU1670711040.USD","IE00B7SZL793.SGD","LU1868836914.USD","LU1291159041.SGD","TEN","BK4201","BK4213","LU0868494617.USD","LU1571399168.USD","ORR","LU0237698245.USD","LU1868837136.USD","LU0306807586.USD","LU0306806265.USD","BK4532","RCC","BK4097","AEIS","LU0321505439.SGD","LU0321505868.SGD","LU0061475181.USD","LU1032466523.USD","HCC","LU1868837300.USD","LU2125154935.USD","LU1670710588.SGD","BK4132","BK4581","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU1261432733.SGD","EC","LU2242646821.SGD","BMY","ALK","CRT","LU0096364046.USD","BK4124","LU1430594728.SGD","LU0225284248.USD","BK4157","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2517132956","title":"HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2517132956","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517132956?lang=en_us&edition=fundamental","pubTime":"2025-03-06 18:00","pubTimestamp":1741255200,"startTime":"0","endTime":"0","summary":"The first patient received the first dose in March 2023 and HUTCHMED expects to announce topline results from the study around the end of 2025. If favorable, the results could enable a New Drug Application submission to China’s National Medical Products Administration .Fanregratinib  is a novel, highly selective and potent inhibitor targeting FGFR 1, 2and3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings.HUTCHMED currently retain all rights to fanregratinib worldwide.This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-announces-completed-enrollment-phase-100000900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4531","PFS","BK4588","BK4195","BK4007","BK4097","ORR","BK4211","BK4585","HCM"],"gpt_icon":0},{"id":"2517978922","title":"Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978922","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978922?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:00","pubTimestamp":1741215600,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, March 05, 2025  -- Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation  by the Center for Drug Evaluation  of China’s National Medical Products Administration , for combination with low-intensity chemotherapy for the first-line treatment of newly-diagnosed patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia .This marks the third BTD granted to olverembatinib in China, with the first BTD granted in March 2021, for the treatment of patients with chronic-phase chronic myeloid leukemia  resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors ; and the second BTD granted in June 2023, for the treatment of patients with succinate dehydrogenase -deficient g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/olverembatinib-granted-breakthrough-therapy-designation-230000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1571399168.USD","ALL","BK4588","LU0985320562.USD","LU1699723380.USD","CDE","AAPG","BK4017","BK4097","OS","BK4139","BK4533","BK4585","BK4107","LU2355687059.USD"],"gpt_icon":0},{"id":"2516622921","title":"TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622921","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622921?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:00","pubTimestamp":1741086000,"startTime":"0","endTime":"0","summary":"New indication based on results from a global Phase 3 trial demonstrating significantly improved overall survival benefit for PD-L1 positive patients treated with TEVIMBRA in combination with chemotherapy. SAN MATEO, Calif., March 04, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration  has approved TEVIMBRA , in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma  whose tumors express PD-L1 (≥1).\"The approval of TEVIMBRA in combination with chemotherapy for adult patients with ESCC expands first-line treatment options for patients with this disease,\" said Dr. Nataliya Uboha, Associate Professor, University of Wisconsin, Carbone Cancer Center. \"There is a critical need for effective treatments of ESCC, and TEVIMBRA has been shown to improve outcomes in this patient population","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevimbra-approved-u-first-line-110000996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITT","LU0054578231.USD","HSCT","BK4161","LU0053666078.USD","TEN","IE00B19Z4B17.USD","IE0031619046.USD","AEIS","BK4585","BK4139","IE00B7SZL793.SGD","BK4157","BK4124","L","BK4588","LU0053671581.USD","OS","BK4097","IE00B66KJ199.SGD","BK4144","ONC","BK4107"],"gpt_icon":0},{"id":"2516920633","title":"ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516920633","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516920633?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:00","pubTimestamp":1741006800,"startTime":"0","endTime":"0","summary":"Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer. DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU. TOKYO & BASKING RIDGE, N.J., March 03, 2025----Positive topline results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU  demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival  compared to ramucirumab and paclitaxel in patients with second-line HER2 positive  unresectable and/or metastatic gastric or gastroesophageal junction  adenocarcinoma.\"We are committed to advancing the care of patients with metastatic gastric cancer and continuing to understand the role of ENHERTU in earlier lines of treatment,\" said Susan Galbraith, MBBChir, PhD, Executive Vice President, Oncology Hematology R&D, AstraZeneca. \"The results of DESTINY-Gastric04 show that second-line treatment with ENHERTU can extend surv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-demonstrated-statistically-significant-clinically-130000294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4225","PBD","BK4203","BK4097","HR","BK4007","DSKYF","BK4231","BK4080","ADC","DSNKY"],"gpt_icon":0},{"id":"2516236371","title":"Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2516236371","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516236371?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:46","pubTimestamp":1740753960,"startTime":"0","endTime":"0","summary":"This week, Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants. AstraZeneca’s AZN phase III study on breast cancer candidate, camizestrant, meets its primary endpoint. The FDA granted priority review to a supplemental biologics license application  seeking approval for expanded use of Merck’s MRK blockbuster drug, Keytruda, in head and neck squamous cell carcinoma .Here's a recap of the week’s most important stories.LLY to Invest $27B to Expand U.S. Manufacturing Sites. The study’s key secondary endpoints were time to second disease progression  and overall survival . The secondary endpoints were immature at the time of this interim analysis. However, an improving trend in PFS2 was observed for the camizestrant combination arm. The study will continue to assess the secondary endpoints.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-lly-ups-144600821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","LU1571399168.USD","BK4568","LU1623119135.USD","BK4516","LU0320765992.SGD","LU0265550946.USD","LU2324357040.USD","LLY","LU0320765489.SGD","LU1868837300.USD","OS","LU1023059063.AUD","LU0256863902.USD","LU0672654240.SGD","LU0861579265.USD","LU2361044949.HKD","BK4007","IE00B4R5TH58.HKD","LU0471298694.HKD","LU1064131342.USD","LU2461242641.AUD","LU1929549753.HKD","LU0965509101.SGD","LU1585245621.USD","LU1267930730.SGD","LU1066051225.USD","LU1551013425.SGD","LU1988902786.USD","SG9999002232.USD","IE0004445239.USD","LU0094547139.USD","LU0198837287.USD","LU1035775433.USD","LU1814569148.SGD","LU1366192091.USD","LU2211815571.USD","LU0211331839.USD","MRK","AZN","LU2357305700.SGD","LU0114720955.EUR","LU2468319806.SGD","SG9999001176.USD","LU0096364046.USD","LU0203201768.USD","LU0106261372.USD","LU0820561818.USD","LU1720051108.HKD","LU0203347892.USD"],"gpt_icon":1},{"id":"2514189327","title":"Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2514189327","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514189327?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc.  and OS Therapies Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calidi-biotherapeutics-os-therapies-interviews-140000113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4561","BK4581","03160","BK4604","ADC","OSTX","BK4097","CLDI","BK4187","BK4099","ET","BK4231","BK4555","TM","TV","AIRI","BK4590","BK4100","OS","BK4588","BK4585","BK4080","BK4144"],"gpt_icon":0},{"id":"2514324925","title":"Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2514324925","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514324925?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:14","pubTimestamp":1740748440,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the Phase 3 BRUIN CLL-321 trial, recently presented at the 2024 American Society of Hematology Annual Meeting. BRUIN CLL-321 is the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The positive opinion is supported by data from the BRUIN CLL-321 clinical trial, the first randomized Phase 3 study in CLL ever conducted exclusively in patients previously treated with a BTK inhibitor. The study's primary endpoint of progression-free survival  was met at the prespecified time of final analysis , based on independent review committee  assessment, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab  or bendamustine plus rituximab , both global standards of care.1 At an updated analysis , pirtobrutinib reduced therisk of disease progressionor death by 46% compared to IdelaR or BR, consistent with the primary analysis.PFS results were cons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-jaypirca-pirtobrutinib-recommended-chmp-131400700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443382.USD","LU2491050071.SGD","LU1023059063.AUD","LU0390134368.USD","PFS","LU2211815571.USD","LU2265009873.SGD","LU2063271972.USD","PRO","LU1974910355.USD","IE0002141913.USD","BK4226","LU2602419157.SGD","LU2361045086.USD","LU2237443978.SGD","OS","IE0009355771.USD","FL","LU0354030511.USD","LLY","LU0238689110.USD","LU0640476718.USD","LU2237443622.USD","BK4533","ORR","BK4516","BK4109","LU1069344957.HKD","LU0471298777.SGD","LU1720051108.HKD","BK4094","LU1814569148.SGD","BK4588","LU1267930730.SGD","LU0203202063.USD","IE00BK4W5L77.USD","BR","BK4599","SG9999015986.USD","CHMP","IE00BJT1NW94.SGD","SG9999001176.USD","LU0203201768.USD","ASH","LU2237443465.HKD","BK4585","LU1061106388.HKD","LU0882574139.USD","LU2461242641.AUD","BNTX"],"gpt_icon":1},{"id":"2514375360","title":"IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514375360","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514375360?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:07","pubTimestamp":1740737220,"startTime":"0","endTime":"0","summary":"Imunon, Inc.  is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin -12 expressing plasmid that allows for the durable, local, and targeted expression of IL-12 in the peritoneum. IL-12 is a potent pro-inflammatory cytokine that mediates a number of important cellular processes, including T cell and natural killer cell activation , the production of interferon-gamma , and alteration of myeloid-derived suppressor cells in the tumor microenvironment . While shown to be effective in pre-clinical tumor models, IL-12 therapy initially showed underwhelming results in the clinic along with very high levels of toxicity when administered systemically. This is likely due to the fact that the direct targets of IL-12 are not circulating lymphocytes, but rather immune cells located within the tumor and lymph nodes. Thus, while systemi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imnn-phase-3-ovarian-cancer-100700685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4203","LU0882574139.USD","CBD","BK4113","ITT","LU0149725797.USD","LU0971096721.USD","LU0053671581.USD","BK4161","BK4139","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","OS","IE00BHPRN162.USD","BK4225","LU1363072403.SGD","LU0170899867.USD","LU0267386448.USD","CMC","IMNN","LU0054578231.USD","BK4097","IE00BZ1G4Q59.USD","HR"],"gpt_icon":0},{"id":"2514368318","title":"ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514368318","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514368318?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:10","pubTimestamp":1740701400,"startTime":"0","endTime":"0","summary":"Regenerative Medicine Advanced Therapy  designation follows clinical data of Absolute Lymphocyte Count  and significant Overall Survival  correlations in QUILT trials across multiple tumor types, including third line or greater metastatic pancreatic cancer, checkpoint relapsed NSCLC, and supportive data from healthy volunteers. The reversal of lymphopenia by ImmunityBio’s IL-15 superagonist is consistent with the mechanism of action of ANKTIVA demonstrating proliferation and activation of NK cells, CD4+ T cells, CD8+ T cells and memory T cells without upregulation of suppressive T regulatory cells and approved in the ANKTIVA label. However, chemotherapy and radiation has also caused a reduction in the very cells necessary to kill cancer cells. This reduction in the lymphocytes by our standard of care also inhibits the induction of T cell memory in the absence of CD4+, CD8+ T cells. A treatment for the reversal of these adverse events of lymphopenia, induced by current standard-of-care,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunitybio-receives-fda-rmat-designation-001000822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CPI","SMP","BK4198","IE00B7SZL793.SGD","LU2265009873.SGD","OS","BK4157","BK4097","BK4230","BK4139","BCG","LU1804176565.USD","IE00B66KJ199.SGD","BK4022","IE00B19Z4B17.USD","BK4135","BK4124","AEIS","ALC","BK4534","CAR","IBRX","IE0031619046.USD"],"gpt_icon":0},{"id":"2514358910","title":"Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358910","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358910?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:00","pubTimestamp":1740690000,"startTime":"0","endTime":"0","summary":"-- Presented positive preliminary data at ASH 2024 from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel in patients with RRMM which demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months --. -- No delayed neurotoxicities observed with anito-cel, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome in 155 patients dosed across the Phase 1 and iMMagine-1 studies as presented at ASH 2024 --. -- iMMagine-1 update planned for presentation mid-year 2025 --. -- Commercial launch of anito-cel in RRMM planned for 2026 --. -- Ended the quarter with $626M, reiterating cash runway into 2027 --. REDWOOD CITY, Calif., February 27, 2025----Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcellx-provides-fourth-quarter-end-210000599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4097","ACLX","BK4139"],"gpt_icon":0},{"id":"2514596802","title":"IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2514596802","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514596802?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:05","pubTimestamp":1740661500,"startTime":"0","endTime":"0","summary":"IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 20","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033835/0/en/IMUNON-Reports-2024-Financial-Results-and-Provides-Business-Update-Highlighting-Significant-Progress-Towards-the-Initiation-of-a-Pivotal-Phase-3-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","LU0882574139.USD","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","BK4097","BK4080","LU0267386448.USD","LU2065732104.USD","OS","IE00BZ1G4Q59.USD","PFS","LU1363072403.SGD","BK4195","CMC","BK4211","BK4139","LU0149725797.USD","BK4006","BK4203","PRGS","BK4225","IMNN","HR","BK4231","LU0971096721.USD","SITC","IE00BHPRN162.USD"],"gpt_icon":0},{"id":"2514895520","title":"Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications","url":"https://stock-news.laohu8.com/highlight/detail?id=2514895520","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514895520?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:48","pubTimestamp":1740606480,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., February 26, 2025----Agenus Inc. , a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and cell therapies . Our most advanced antibody candidates, botensilimab  an Fc-enhanced CTLA-4 blocking antibody, and balstilimab , a novel, PD-1 inhibitor, are central to our efforts.BOT is currently being investigated as a monotherapy and in combination with widely used standard of care anti-PD-1, chemotherapy, and allogeneic cell therapy across multiple indications:. Dr. O’Day continues, \"By leveraging our deep expertise in immune activation, we are unlocking responses in tumors previously resistant to immunotherapy. The results are even more promising as we move from treatment refractory me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agenus-reports-impact-key-immuno-214800977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","OS","BK4097","BK4195","BK4232","CRC","BAL","ORR","R","BK4022","BK4139","BK4213","MSS","LU0266512127.USD","PFS","AGEN","BK4113","LU0456854461.SGD"],"gpt_icon":0},{"id":"2514867732","title":"Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867732","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867732?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:02","pubTimestamp":1740603720,"startTime":"0","endTime":"0","summary":"Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026. Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer. Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025. Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time. REDWOOD CITY, Calif., Feb. 26, 2025  -- Revolution Medicines, Inc. , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2024, and provided an update on corporate progress.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revolution-medicines-reports-fourth-quarter-210200565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","LU0348723411.USD","OS","LU2298322129.HKD","IE00B19Z3B42.SGD","BK4512","LU1861214812.USD","BK4503","NE","LU1548497426.USD","PFS","BK4195","IE00BZ199S13.USD","LU1854103824.USD","CI","LU2357305700.SGD","LU1978683503.SGD","ON","BK4097","IE00B19Z3581.USD","LU1854104046.USD","IE00B7SZLL34.SGD","BK4092","BK4211","BK4605","LU1059921491.USD","MDCO","LU2360107325.USD","LU0058720904.USD","RVMDW","PRGS","RVMD","BK4585","BK4563","LU1720051108.HKD","BK4139","LU2065732104.USD","LU1861219969.SGD","BK4166","IE0002270589.USD","LU0724618433.USD","LU0868494617.USD","LU1720051017.SGD","LU1861220033.SGD","LU0124384867.USD","QD","LU0289739699.SGD","LU1861215975.USD","BK4588","IE00BD6J9T35.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5714,"hold":0.0952,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":21,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-06-13","current":-21.083062,"percent":0.688372,"low":-1655.61542,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"high":-14.493656,"avg":-366.615877,"sd":586.069132,"marketCap":4959958960},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960}],"updateTime":1750071672882}}}